logo
  

Kazia Reports Promising Interim Data From Phase I Trial Of Paxalisib

Kazia Therapeutics Limited (KZIA) reported promising new data from an ongoing phase I clinical trial of paxalisib in combination with radiotherapy for the treatment of brain metastases. The interim data from the first stage of the study showed that all 9 evaluable patients experienced complete or partial response, representing an overall response rate of 100%. The company noted that recruitment to the expansion stage has already commenced, with the objective of recruiting an additional 12 patients.

Kazia CEO, James Garner, said, "Radiotherapy is a ubiquitous component of the treatment paradigm for brain metastases, but resistance is common. Dr. Yang's study has shown a very promising signal that paxalisib may help to potentiate the effect of radiotherapy."

Kazia currently estimates preliminary data from the second part of the phase I clinical trial in calendar year 2023.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT